Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: difference between HCV genotypes 1b and 2

Hepatology International

Volumn 8, Issue 4, 2014, Pages 550-559

  Seki, Nobuyoshi ^a   Sugita, Tomonori ^a   Aida, Yuta ^a   Itagaki, Munenori ^a   Ishiguro, Haruya ^a   Sutoh, Satoshi ^a   Abe, Hiroshi ^a   Tsubota, Akihito ^b   Matsushima, Masato ^b   Aizawa, Yoshio ^a  

^a Jikei University School of Medicine   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apolipoprotein; Genotype; Hepatitis C; Lipid metabolism

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; INTERFERON; INTERLEUKIN 28B; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; JAPANESE (PEOPLE); LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED;

EID: 84919848255     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-014-9572-2     Document Type: Article

References (31)

1. World Health Organization. World Health Organization. Media Centre. July 2013. http://www.who.int/mediacentre/factsheets/fs164/en/
2. Murray R, Bender D. Botham KM, Kennelly PJ, Rodwell V, Weil PA. Harper’s Illustrated Biochemistry. 29th ed. US: McGraw-Hill Medical; 2012
3. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006;80:2418–2428
4. Jiang J, Wu X, Tang H, Luo G. Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors. PLoS One 2013;8(7):e67982
5. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003–1008
6. Yamane D, McGivern DR, Masaki T, Lemon SM. Liver injury and disease pathogenesis in chronic hepatitis C. Curr Top Microbiol Immunol 2013;69:263–288
7. Rojas ÁJA, del Campo JA, Maraver M, Aparcero R, García-Valdecasas M, Diago M, et al. Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro. J Viral Hepat 2014;21:19–24
8. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995;171:1607–1610
9. Rowell J, Thompson AJ, Guyton JR, Lao XQ, McHutchison JG, McCarthy JJ, et al. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol Int 2012;6:475–481
10. Moriya K, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Yotsuyanagi H, et al. Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res 2003;25:371–376
11. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001;34:428–434
12. Bridge SH, Sheridan DA, Felmlee DJ, Nielsen SU, Thomas HC, Taylor-Robinson SD, et al. Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection. Gut 2011;60:680–687
13. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002;16:185–194
14. Chayama K, Tsubota A, Arase Y, et al. Genotypic subtyping of hepatitis C virus. J Gastroenterol Hepatol 1993;8:150–156
15. Fujie H, Yotsuyanagi H, Moriya K, Shintani Y, Tsutsumi T, Takayama T, et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999;59:141–145
16. Miyajima I, Kawaguchi T, Fukami A, Nagao Y, Adachi H, Sasaki S, et al. Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: a population-based study in an HCV hyperendemic area. J Gastroenterol 2013;48:93–100
17. Sato S, Genda T, Hirano K, Tsuzura H, Kanemitsu Y, Narita Y, et al. Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C. Hepatol Int 2013;7:508–515
18. Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RD. Lipids and HCV. Semin Immunopathol 2013;35:87–100
19. Simmonds P, Mellor J, Sakuldamrongpanich T, Nuchaprayoon C, Tanprasert S, Holmes EC, et al. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. J Gen Virol 1996;77:3013–3024
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502
21. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317–1325
22. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32–36
23. Syvänne M, Kahri J, Virtanen KS, Taskinen MR. HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation 1995;92:364–370
24. Kim K, Kim KH, Ha E, Park JY, Sakamoto N, Cheong J. Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Lett 2009;583:2720–2726
25. Thulin P, Glinghammar B, Skogsberg J, Lundell K, Ehrenborg E. PPARdelta increases expression of the human apolipoprotein A-II gene in human liver cells. Int J Mol Med 2008;21:819–824
26. Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab 2011;96:E1568–E1576
27. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995;270:13470–13475
28. Hueging K, Doepke M, Vieyres G, Bankwitz D, Frentzen A, Doerrbecker J, et al. Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. J Virol 2014;88:1433–1446
29. Sheridan DA, Bridge SH, Felmlee DJ, Crossey MM, Thomas HC, Taylor-Robinson SD, et al. Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. J Hepatol 2012;57:32–38
30. Yoshizawa K, Abe H, Aida Y, Ishiguro H, Ika M, Shimada N, et al. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. J Med Virol 2013;85:1180–1190
31. Aizawa Y, Yoshizawa K, Aida Y, Ishiguro H, Abe H, Tsubota A. Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. Mol Cell Biochem 2012;360:9–14